# Iambic Therapeutics

**Canonical:** https://apis.io/providers/iambic-tx/  
**Website:** https://www.iambic.ai  
**APIs profiled:** 0

Iambic Therapeutics is a San Diego, California AI-driven drug discovery company founded in 2019 by Thomas Miller (CEO) and Fred Manby (CTO) that designs small-molecule therapeutics for oncology and other indications. Iambic builds proprietary AI models for drug discovery, including Enchant, a multimodal transformer that predicts clinical properties (pharmacokinetics, cellular and biochemical activity) of candidate molecules from early discovery data, and NeuralPLexer (now NeuralPLexer3), a flow-based generative model for protein-ligand complex structure prediction used to identify cryptic pockets and guide structure-based design. Both lines of work have been published at venues including NeurIPS 2025. The company's internal pipeline is oncology-led: IAM1363, a brain-penetrant selective HER2 / HER2-mutant inhibitor, completed Phase 1/1b dose escalation in 2025 and is in dose optimization with clinical activity reported at ESMO 2025; IAM-K1 (KIF18A) and IAM-C1 (CDK2/4) are preclinical, alongside undisclosed neurology, gastrointestinal, and inflammation discovery programs. In February 2026 Iambic announced a discovery and technology collaboration with Takeda worth up to ~$1.7B plus royalties, following a $100M+ private financing in November 2025 and total disclosed funding of approximately $334M. The company has been named to the CNBC Disruptor 50 list in 2025 and 2026 and has signaled intent to access public markets, including via a SPAC. Iambic's public GitHub footprint is limited to np-bench, a BSD-3 benchmark library for 3D biomolecular structure prediction; the underlying NeuralPLexer and Enchant models are proprietary and there is no public developer API, SDK, or commercial platform offering.

## Kin Score — 6.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 6.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 5.3 |
| Developer Ergonomics | 2.4 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Iambic Tx Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

AI Drug Discovery, Drug Discovery, Therapeutics, Oncology, Small Molecules, HER2, KIF18A, CDK2 CDK4, Multimodal Transformers, Structure Prediction, Protein Ligand, Enchant, NeuralPLexer, Biotech, San Diego

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/iambic-tx/). Scores are computed from the provider's own public artifacts under a published rubric.